查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835398

關節痛注射劑市場（按分子類型、適應症、給藥途徑、最終用戶和患者年齡層分類）—全球預測，2025-2032

Joint Pain Injections Market by Molecule Type, Indication, Route Of Administration, End User, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年關節痛注射劑市場規模將達到 118.5 億美元，複合年成長率為 11.25%。

主要市場統計數據
基準年2024年 50.4億美元
預計2025年 56.2億美元
預測年份：2032年 118.5億美元
複合年成長率（%） 11.25%

為決策者全面介紹影響全球關節痛注射生態系統的臨床、技術和商業性促進因素

隨著臨床醫生尋求有效、有針對性的干涉措施，以最大程度地減輕症狀並縮短恢復期，關節疼痛注射已成為現代整形外科、風濕病學和運動醫學的核心。在過去十年中，臨床醫生在現有的皮質類固醇注射療法與不斷擴展的生物製藥和關節內粘稠補充療法之間取得了平衡，技術和影像引導對治療結果的重要性日益凸顯。因此，臨床討論已從單一治療模式轉向以安全性、可重複性和患者報告的功能改善為優先考慮的綜合治療途徑。

如今，臨床醫生和醫療保健系統面臨著巨大的報銷壓力、患者對無針再生療法的需求日益成長，以及對手術部位安全性和文件記錄日益重視等諸多挑戰。此外，微創手術在門診（例如門診手術中心和專科診所）的應用正在加速，這影響著籌資策略和培訓重點。這些因素共同作用，挑戰製造商、設備製造商和臨床服務供應商，他們需要協調產品創新、醫生教育和價值展示，以保持應用率並滿足付款人的期望。

探索加速注射療法治療關節疼痛和改變護理標準的變革性技術、臨床和政策轉變

由於生物製藥、影像學和報銷模式的融合，關節疼痛注射療法的臨床和商業性前景正在發生重大變化。首先，臨床上對再生療法的興趣日益濃厚，已將富血小板血漿和相關的自體血漿療法從小眾選擇提升到主流臨床實驗選擇，促使製造商改進處理試劑套件和品管。同時，改良的透明質酸配方和皮質類固醇的持續使用保持了其治療相關性，但根據患者情況和關節特異性結果，其治療方案會更加細緻。

同時，影像引導介入措施（例如超音波引導注射）正從專科中心走向常規實踐，從而提高了靶向精準度，並強化了其對卓越臨床療效和降低併發症率的主張。醫療系統和支付方正在做出回應，強調程序記錄和真實世界結果，並增加對資料收集和品質登記的投入。最後，隨著供應鏈彈性、本地製造和策略夥伴關係對於管理成本壓力和監管複雜性變得至關重要，該領域的商業邏輯正在轉變。隨著相關人員的適應，將臨床證據產生與臨床醫生培訓和強大的上市後監測相結合的公司將在採用和信任方面實現非對稱優勢。

嚴格分析 2025 年美國關稅如何改變注射關節痛療法的採購、定價和供應鏈策略。

美國2025年實施的關稅變化的累積效應波及了關節疼痛注射劑及其組件的採購、定價和供應鏈決策。某些進口醫療用品的關稅上調，增加了一次性套件、透明質酸起始原料和某些器械組件的到岸成本，促使企業即時與供應商進行談判，並重新評估籌資策略。為此，跨國製造商加快了本地化生產的步伐，將高價值組裝轉移到國內，或在關稅豁免地區重新尋找替代供應商，以減輕利潤率的壓縮。

這種轉變導致採購週期延長，供應商、經銷商和醫療保健提供者組織之間需要重新談判合約並進行成本轉嫁討論。付款人和醫院採購團隊越來越嚴格地審查單位經濟效益和總護理成本，這更凸顯了製造商證明持續臨床效益和成本抵銷的必要性。同時，規模較小的創新者和契約製造製造商面臨越來越大的進入美國市場的障礙，除非他們調整定價模式或建立國內合作夥伴關係。展望未來，法規合規性、關稅分類明確以及雙邊供應商協議已成為相關人員在管理商業性可行性的同時尋求保持准入的關鍵戰術性槓桿。

詳細的細分洞察將分子類型、臨床指徵、給藥途徑、醫療環境和患者人口統計與可行的採用策略聯繫起來

以分子類型評估時，可區分現有的皮質類固醇、各種透明質酸製劑和富血小板血漿方法，每種方法都有不同的臨床和商業性意義。皮質類固醇類別包括已充分錶徵的藥物，例如Betamethasone、Methylprednisolone和曲安奈德，其效力、儲庫行為和症狀緩解持續時間的差異影響著臨床醫生的選擇。透明質酸製劑分為交聯製劑和直鏈製劑；交聯製劑通常旨在延長關節內停留時間和延長症狀控制時間，而直鏈製劑則強調方便、低黏度和即時的關節順應性。富血小板血漿分為白血球貧乏和白血球豐富的製劑；這些生物學差異影響發炎特徵、監管監督和程序處理要求。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 快速採用生物製藥的關節內粘稠補充療法療法治療晚期骨關節炎疼痛
  • 將富血小板血漿注射與個人化再生通訊協定結合，用於關節修復
  • 擴大長效皮質類固醇製劑可減少注射頻率並提高順從性
  • 增加對微創超音波導引注射技術的投資，實現精準給藥
  • 推出結合玻尿酸和幹細胞成分的聯合治療，以提高療效

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章關節痛注射劑市場（依分子類型）

  • 皮質類固醇
    • Betamethasone
    • 醋酸Methylprednisolone
    • 曲安奈德
  • 玻尿酸
    • 交聯
    • 直鏈
  • 富血小板血漿
    • 少白血球
    • 多發性白血球

第9章關節痛注射劑市場（依適應症）

  • 痛風
    • 急性期管理
    • 慢性期管理
  • 骨關節炎
    • 髖關節
    • 膝關節
    • 肩關節
  • 類風濕性關節炎
    • 大關節
    • 小關節

第 10 章關節痛注射劑市場（依給藥途徑）

  • 關節內
    • 地標基地
    • 超音波引導
  • 肌肉注射
    • 深層組織
    • 淺部
  • 關節周圍
    • 地標基地
    • 超音波引導

第 11 章 關節痛注射劑市場（依最終使用者）

  • 門診手術中心
  • 醫院
  • 整形外科診所
  • 風濕病診所

第12章關節痛注射市場（依患者年齡層）

  • 青年
  • 成人
  • 老年人
  • 孩子們

第13章關節痛注射市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章關節痛注射劑市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章關節痛注射劑市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Sanofi SA
    • Ferring Pharmaceuticals A/S
    • Zimmer Biomet Holdings, Inc.
    • Bioventus, Inc.
    • Seikagaku Corporation
    • Anika Therapeutics, Inc.
    • Fidia Farmaceutici SpA
    • Merck & Co., Inc.
    • Johnson & Johnson
    • AbbVie Inc.
Product Code: MRR-43470FC6083D

The Joint Pain Injections Market is projected to grow by USD 11.85 billion at a CAGR of 11.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.04 billion
Estimated Year [2025] USD 5.62 billion
Forecast Year [2032] USD 11.85 billion
CAGR (%) 11.25%

Comprehensive introduction to the clinical, technological, and commercial drivers reshaping the global joint pain injection ecosystem for decision-makers

Joint pain injections occupy a central role in contemporary orthopedics, rheumatology, and sports medicine as clinicians seek effective, targeted interventions that offer symptom relief with minimal downtime. Over the past decade, clinicians have balanced established corticosteroid injections with an expanding repertoire of biologic and viscosupplementation options, while procedural technique and imaging guidance have become increasingly pivotal to outcomes. As a result, the clinical conversation has shifted from single-treatment paradigms toward integrated pathways that prioritize safety, reproducibility, and patient-reported functional gains.

Clinicians and health systems now operate within a context defined by tighter reimbursement pressures, growing patient demand for needle-sparing and regenerative approaches, and heightened attention to procedure-site safety and documentation. In addition, outpatient settings such as ambulatory surgical centers and specialty clinics are accelerating adoption of minimally invasive interventions, which in turn shapes procurement strategies and training priorities. Taken together, these forces are prompting manufacturers, device makers, and clinical service providers to align product innovation, physician education, and value demonstration to sustain adoption and to address payer expectations.

Detailed exploration of transformative technological, clinical, and policy shifts that are accelerating adoption and changing standards of care in joint pain injection therapies

Clinical practice and commercial landscapes for joint pain injections are undergoing transformative shifts driven by converging advances in biologics, imaging, and reimbursement frameworks. First, the increasing clinical interest in regenerative approaches has elevated platelet-rich plasma and related autologous therapies from niche options to mainstream investigational choices, prompting manufacturers to refine processing kits and quality controls. Meanwhile, improvements in hyaluronic acid formulations and the continued use of corticosteroids maintain their therapeutic relevance, but with more nuanced positioning based on patient profile and joint-specific outcomes.

Concurrently, imaging-enabled delivery, most notably ultrasound-guided injections, has moved from specialized centers into routine practice, improving targeting accuracy and reinforcing claims of superior clinical outcomes and reduced complication rates. Health systems and payers are responding by emphasizing procedure documentation and real-world outcomes, which drives greater investment in data capture and quality registries. Finally, the sector's commercial logic is shifting as supply chain resilience, localized manufacturing, and strategic partnerships become critical to managing cost pressures and regulatory complexity. As stakeholders adapt, those who integrate clinical evidence generation with clinician training and robust post-market surveillance will realize asymmetric advantages in adoption and trust.

Rigorous analysis of how U.S. tariff measures enacted in 2025 reshaped sourcing, pricing dynamics, and supply chain strategies for joint pain injection therapies

The cumulative effects of tariff changes implemented in the United States in 2025 have reverberated across procurement, pricing, and supply chain decision-making for joint pain injection products and their components. Increased duties on certain imported medical inputs elevated landed costs for disposable kits, hyaluronic acid starting materials, and certain device components, which in turn prompted immediate supplier negotiations and a reevaluation of sourcing strategies. In response, multinational manufacturers accelerated efforts to localize production, shift higher-value assembly onshore, or requalify alternative suppliers in tariff-exempt jurisdictions to mitigate margin compression.

As a consequence of these shifts, procurement cycles lengthened while contract renegotiations and cost-pass-through discussions took place between suppliers, distributors, and provider organizations. Payers and hospital procurement teams increasingly scrutinized unit economics and total cost of care, reinforcing the need for manufacturers to demonstrate durable clinical benefit and cost-offsets. At the same time, smaller innovators and contract manufacturers faced heightened barriers to entering the U.S. market unless they adapted pricing models or established domestic partnerships. Looking forward, regulatory compliance, customs classification clarity, and bilateral supplier agreements have become critical tactical levers for stakeholders seeking to preserve access while managing commercial viability.

In-depth segmentation insights that connect molecule types, clinical indications, routes of administration, care settings, and patient age cohorts to practical adoption strategies

When evaluated by molecule type, the landscape distinguishes between established corticosteroids, various hyaluronic acid formulations, and platelet-rich plasma approaches, each presenting distinct clinical and commercial implications. The corticosteroid segment includes well-characterized agents such as Betamethasone, Methylprednisolone Acetate, and Triamcinolone Acetonide, with differences in potency, depot behavior, and duration of symptom relief influencing clinician selection. Hyaluronic acid offerings diverge across cross-linked and linear formulations, where cross-linked variants often aim to extend residence time within the joint and target longer symptom control, while linear formulations emphasize simplicity, lower viscosity, and potentially better immediate joint compliance. Platelet-rich plasma is differentiated into leukocyte-poor and leukocyte-rich preparations, and these biologic distinctions affect inflammatory profiles, regulatory oversight, and procedural handling requirements.

Based on indication, treatment pathways vary across gout, osteoarthritis, and rheumatoid arthritis. In gout the focus separates acute management from chronic management, which drives differences in medication choice and urgency of intervention. Osteoarthritis practice differentiates by joint site-hip, knee, and shoulder-with knee injections historically representing the largest procedural volume while hip and shoulder approaches demand higher imaging precision. Rheumatoid arthritis requires a different framing, as care pathways for large joints and small joints prioritize systemic disease control alongside local symptom relief.

Based on route of administration, clinicians select between intra-articular, intramuscular, and peri-articular approaches, with intra-articular procedures further distinguished by landmark-based or ultrasound-guided techniques. Intramuscular injections split into deep tissue and superficial approaches, each with distinct needle selection and recovery considerations, while peri-articular delivery also differentiates by landmark-based versus ultrasound-guided methods that affect accuracy and complication risk. Based on end user, the services are delivered across ambulatory surgical centers, hospitals, orthopedic clinics, and rheumatology clinics, with each setting imposing different credentials, billing pathways, and throughput constraints. Based on patient age group, clinical decision-making must account for adolescents, adults, elderly patients, and pediatrics, where comorbidities, growth considerations, and long-term safety profiles shape both product selection and procedural planning.

Collectively, these multi-dimensional segmentation lenses reveal that clinical adoption and commercial success hinge on aligning formulation properties, delivery technique, and site-of-care logistics with payer expectations and patient-centric outcomes. As a result, product teams and clinician educators must tailor evidence generation and training to specific molecule-route-indication permutations to accelerate acceptance and optimize outcomes.

Key regional perspectives highlighting how reimbursement, regulation, clinical practice patterns, and manufacturing capacity vary across major global regions

Regional dynamics continue to drive differentiated strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting unique regulatory environments, reimbursement frameworks, and clinical practice patterns. In the Americas, a concentrated emphasis on outpatient procedural growth, ambulatory surgical center capacity, and payer scrutiny shapes purchasing and clinical adoption, prompting manufacturers to prioritize evidence demonstrating comparative effectiveness and procedural efficiency. Transitioning from hospital-centric care to decentralized settings has also spurred investment in training programs that help standardize ultrasound-guided techniques across diverse provider networks.

Across Europe, Middle East & Africa, regulatory harmonization and national reimbursement policies create a patchwork of access profiles that favor products with robust clinical data and clear cost-offset narratives. In many jurisdictions, clinicians emphasize long-term safety and quality-of-life metrics, and national procurement bodies often drive volume purchasing decisions that favor standardized, cost-effective options. Meanwhile, in the Asia-Pacific region, rapid adoption of innovative delivery techniques, a growing base of procedure-trained clinicians, and expanding domestic manufacturing capacity are reshaping competitive dynamics. Price sensitivity coexists with a strong interest in regenerative and minimally invasive approaches, encouraging hybrid strategies that combine localized production with targeted clinical evidence generation. Understanding these regional contours enables manufacturers and service providers to tailor regulatory strategies, distribution partnerships, and evidence programs to region-specific priorities and payer architectures.

Strategic company-level insights revealing how partnerships, portfolio integration, and evidence generation shape competitive advantages in joint pain injection offerings

Competitive dynamics among companies operating in the joint pain injection space reflect strategic moves to integrate product portfolios, expand service offerings, and secure distribution channels. Established pharmaceutical manufacturers continue to optimize corticosteroid and hyaluronic acid lines while selectively investing in specialty biologics and device-enabled delivery solutions. At the same time, device and diagnostic firms are partnering with biologic innovators to offer bundled solutions that combine injectables with guidance systems, procedural kits, and clinician training-strengthening the value proposition for providers and payers.

Newer entrants and mid-sized firms often differentiate through processing innovations for autologous therapies, streamlined disposables, or cost-effective kit designs that address site-of-care constraints. Across the competitive set, a consistent strategic theme is the pursuit of integrated evidence-generation programs that couple randomized clinical studies with real-world registries and patient-reported outcome capture. Additionally, companies are reallocating commercial investments toward outpatient channels, direct clinician education, and contracting models that align pricing with demonstrated outcomes. As a result, partnerships, licensing agreements, and selective vertical integration are emerging as preferred pathways to scale while managing regulatory complexity and capital intensity.

Actionable recommendations for manufacturers, clinicians, and payers to build supply resilience, validate clinical value, and accelerate adoption across care settings

Industry leaders should prioritize a set of pragmatic actions to translate insight into resilient growth and clinical impact. First, invest in supply chain resilience by diversifying suppliers, qualifying domestic manufacturing partners where feasible, and maintaining clear customs and classification strategies; doing so reduces exposure to tariff shocks and short-term disruptions. Second, commit to clinician training programs that emphasize ultrasound-guided delivery and standardized protocols, because procedural accuracy directly influences perceived effectiveness and payer acceptance.

Third, align product development with indication-specific evidence plans that address the clinical questions most relevant to payers and high-volume providers; this includes targeted outcomes for hip, knee, and shoulder interventions, and comparative analyses relative to systemic therapies in inflammatory conditions. Fourth, build modular commercial models that accommodate ambulatory surgical centers, hospitals, and specialty clinics, enabling flexible contracting and tiered pricing that reflect differing site-of-care economics. Fifth, pursue partnerships that integrate delivery devices, digital outcome capture, and post-market registries to substantiate value. Finally, adopt a patient-centric communications strategy that emphasizes safety, recovery timelines, and functional outcomes to improve uptake and reduce friction at the point of care. Collectively, these steps create an aligned playbook that balances short-term resilience with long-term clinical credibility.

Transparent description of the mixed-method research approach combining clinician interviews, supplier intelligence, regulatory review, and expert validation to produce robust insights

This analysis relied on a multi-method research approach that combined primary qualitative engagement with validated secondary intelligence to ensure balanced and auditable insights. The primary research included in-depth interviews with practicing orthopedic surgeons, rheumatologists, interventional radiologists, and procedure nurses, as well as structured discussions with procurement leads and regulatory experts across major regions. These interviews were supplemented by advisory-panel workshops that stress-tested hypotheses and prioritized evidence needs.

Secondary research incorporated review of peer-reviewed clinical literature, regulatory filings, product labels, and device guidance documents to map clinical indications, contraindications, and procedure protocols. The methodology also leveraged supplier and distributor interviews to assess supply chain pathways, lead times, and contractual norms. Data synthesis applied rigorous qualitative coding and triangulation to reconcile divergent viewpoints, and findings were validated through an expert review process to ensure credibility. Where appropriate, real-world practice patterns were inferred from clinical guidelines and procedural training curricula to contextualize adoption dynamics. Throughout, the research team adhered to transparent data provenance, strict conflict-of-interest checks, and iterative validation with clinical advisors to maintain robustness and relevance.

Concise conclusion drawing together clinical innovation, procedural trends, and commercial imperatives to define strategic priorities for stakeholders

The joint pain injection landscape is at an inflection point where clinical innovation, procedural precision, and commercial pragmatism intersect. Advances in biologic processing, more effective hyaluronic acid chemistries, and wider adoption of imaging-guided techniques are redefining expectations around safety and efficacy, while payer and procurement scrutiny drive the need for rigorous outcome evidence. At the same time, policy actions such as tariffs have emphasized the importance of supply chain strategy and local manufacturing decisions in preserving access and sustainable pricing.

For stakeholders across the value chain, the imperative is clear: align product development with indication- and route-specific evidence, invest in clinician training to secure consistent delivery quality, and adopt flexible commercial models that reflect diverse site-of-care economics. By doing so, manufacturers and providers can both improve patient outcomes and create defensible positions in a market characterized by rapid clinical evolution and intensified operational scrutiny. The next phase will reward organizations that marry clinical credibility with operational agility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of biologic-based viscosupplementation formulas targeting advanced osteoarthritis pain
  • 5.2. Integration of platelet-rich plasma injections with personalized regenerative protocols for joint repair
  • 5.3. Expansion of long-acting corticosteroid formulations reducing injection frequency and improving compliance
  • 5.4. Growing investment in minimally invasive ultrasound-guided injection techniques for precise drug delivery
  • 5.5. Emergence of combination therapies blending hyaluronic acid with stem cell components for enhanced efficacy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Joint Pain Injections Market, by Molecule Type

  • 8.1. Corticosteroids
    • 8.1.1. Betamethasone
    • 8.1.2. Methylprednisolone Acetate
    • 8.1.3. Triamcinolone Acetonide
  • 8.2. Hyaluronic Acid
    • 8.2.1. Cross-Linked
    • 8.2.2. Linear
  • 8.3. Platelet-Rich Plasma
    • 8.3.1. Leukocyte-Poor
    • 8.3.2. Leukocyte-Rich

9. Joint Pain Injections Market, by Indication

  • 9.1. Gout
    • 9.1.1. Acute Management
    • 9.1.2. Chronic Management
  • 9.2. Osteoarthritis
    • 9.2.1. Hip
    • 9.2.2. Knee
    • 9.2.3. Shoulder
  • 9.3. Rheumatoid Arthritis
    • 9.3.1. Large Joints
    • 9.3.2. Small Joints

10. Joint Pain Injections Market, by Route Of Administration

  • 10.1. Intra-Articular
    • 10.1.1. Landmark-Based
    • 10.1.2. Ultrasound-Guided
  • 10.2. Intramuscular
    • 10.2.1. Deep Tissue
    • 10.2.2. Superficial
  • 10.3. Peri-Articular
    • 10.3.1. Landmark-Based
    • 10.3.2. Ultrasound-Guided

11. Joint Pain Injections Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Orthopedic Clinics
  • 11.4. Rheumatology Clinics

12. Joint Pain Injections Market, by Patient Age Group

  • 12.1. Adolescents
  • 12.2. Adults
  • 12.3. Elderly
  • 12.4. Pediatrics

13. Joint Pain Injections Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Joint Pain Injections Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Joint Pain Injections Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Sanofi S.A.
    • 16.3.2. Ferring Pharmaceuticals A/S
    • 16.3.3. Zimmer Biomet Holdings, Inc.
    • 16.3.4. Bioventus, Inc.
    • 16.3.5. Seikagaku Corporation
    • 16.3.6. Anika Therapeutics, Inc.
    • 16.3.7. Fidia Farmaceutici S.p.A.
    • 16.3.8. Merck & Co., Inc.
    • 16.3.9. Johnson & Johnson
    • 16.3.10. AbbVie Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. JOINT PAIN INJECTIONS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. JOINT PAIN INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. JOINT PAIN INJECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA JOINT PAI